Navigation Links
Aida Announces New Anti-Cancer Drug Under Development
Date:4/18/2008

SANTA MONICA, Calif., April 18 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) (hereinafter referred to as "Aida") today announced that it is developing a potential cancer drug that seeks to trigger cell death in certain types of cancer. Vasostatin-Apo2L, a pre-clinical product being developed by Aida's Shanghai Qiaer subsidiary, is a recombinant fusion protein that integrates the function of extracted fragments of Vasostatin, an inhibitor of angiogenesis and tumor growth, with the function of Rh-Apo2L, which induces the apoptosis of cancer cells. It has shown positive results in the lab. Aida's researchers believe that the integration of Vasostatin-Apo2L will have higher efficacy in certain cancer treatments than currently prescribed methods.

Aida estimates that Vasostatin will have a target market of 80,000-100,000 patients per year after it is successfully brought to market and this will contribute significantly to Aida's revenue.

Vasostatin-Apo2L is developed by the same research team that created Rh-Apo2L. Rh-Apo2L has successfully completed its Phase 2 clinical testing and is going to file application with the PRC government's State Food and Drug Administration to start the Phase III trials. The development of Vasostatin-Apo2L will benefit strongly from the experience garnered in the research, manufacturing and distribution of Rh-Apo2L.

About Aida Pharmaceuticals

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO90
'/>"/>

SOURCE Aida Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Norgine B.V. today announced that the Phase ... NER1006, presented at the 79 th Annual Scientific ... Philadelphia, PA , has met its primary ... of cleansing success. The study demonstrated high quality bowel ... screening colonoscopy patients. [1] (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a) ...
(Date:10/19/2014)... Wash. , Oct. 20, 2014 CTI ... that it will report its third quarter 2014 financial ... of the U.S. financial markets. Following the announcement, members ... call to discuss the results and provide a general ... Access to the event can be obtained as follows: ...
(Date:10/18/2014)... , Oct. 18, 2014  In a ... Rights Campaign (HRC), the nation,s largest lesbian, gay, ... endorsed the use of Truvada for Pre-Exposure Prophylaxis ... tool used to prevent the spread of a ... the only brand name anti-HIV drug combination currently ...
Breaking Medicine Technology:Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3
... Milestone Scientific Inc. (OTCQB: MLSS), the recognized leader ... filed its 2010 year-end results for the 12 months ... Exchange Commission on Wednesday, March 30, 2011. ... April 4, 2011 beginning at 4:15 PM Eastern Daylight ...
... UBM Canon and IVD Technology ... The Fundamentals of In Vitro Diagnostics. This one-hour event will ... and will offer an in-depth analysis and discussion from ... With the advent of the sequencing of ...
Cached Medicine Technology:Milestone Scientific Will Host Its 2011 Conference Call on Monday, April 4, 2011 2"IVD Technology" Announces Upcoming Webcast: Omics and the Development of IVDs 2"IVD Technology" Announces Upcoming Webcast: Omics and the Development of IVDs 3
(Date:10/20/2014)... 20, 2014 Punzoné , the first ... U.S., has a lot to celebrate this month. October marks ... the achievements and contributions of Americans of Italian heritage and ... and today it shares its favorite Italian cocktails and encourages ... Italy - even if it is only in a glass. ...
(Date:10/20/2014)... 2014 Do you ever feel difficulty ... a wonderful app Metassessor for teachers, specialists and parents. ... helped its client “Intervention Development LLC” to launch Metassessor ... designed for iOS 4.3 or later and is Compatible ... optimized for iPhone 5. It is now available on ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has ... GreenGeeks are the best Dedicated Server Hosting suppliers. ... want to buy high quality hosting and save ... manager of Top10BestSEOHosting.com says, “We believe that iPage ... everyone. A lot of the global clients enjoy ...
(Date:10/19/2014)... York (PRWEB) October 19, 2014 Dr. ... Population Fund, welcomes news of a ceasefire agreement that ... more than 200 girls who were kidnapped from the ... have languished in captivity long enough, and it is ... and communities," stated Dr. Osotimehin. , "We owe it ...
(Date:10/19/2014)... working in the garment industry for decades, LunaDress’ dress specialists ... one of the company’s top designers, many ladies like prom ... add beauty to them. Chiffon floor length outfits are also ... selection of 2014 long prom dresses. , As a ... in over 20 popular designs. The company intends to meet ...
Breaking Medicine News(10 mins):Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
... , THURSDAY, Oct. 13 (HealthDay News) --,Smoking ... are genetically susceptible to the mental health disorder, according ... population have the variant of the serotonin gene (5-HTT) ... Radboud University Nijmegen in the Netherlands. They analyzed ...
... CHINA (October 13, 2011) Autism Speaks, the world,s ... largest genomic organization in the world and a global ... to create the world,s largest library of sequenced genomes ... Autism Speaks Autism Genetic Resource Exchange (AGRE), this collaboration ...
... will benefit from a new, pan-Canadian Terry Fox Research ... in which ovarian cancer is diagnosed and managed. ... a total of $5-million in funding for a five-year, ... will identify new biomarkers to predict and treat this ...
... disparities between Latinos and non-Latino whites, mostly from a policy ... perspective of the patient, in terms of access, use and ... how do the physicians feel about the quality of care ... patients, compared with physicians whose patients are primarily white and ...
... Maureen Salamon HealthDay Reporter , WEDNESDAY, Oct. ... esophageal cancer for patients with a condition known as ... once reported, a large new Danish study suggests. ... people, researchers determined that those with Barrett,s esophagus -- ...
... , WEDNESDAY, Oct. 12 (HealthDay News) -- Black Americans ... cancer have worse overall and recurrence-free survival rates than whites, ... nearly 15,000 black and white colorectal cancer surgery patients who ... between 1977 and 2002. All the patients received the same ...
Cached Medicine News:Health News:Autism Speaks and BGI to complete whole genome sequencing on 10,000 with autism 2Health News:Terry Fox Research Institute aims to change diagnosis and management of ovarian cancer worldwide 2Health News:Terry Fox Research Institute aims to change diagnosis and management of ovarian cancer worldwide 3Health News:Physicians treating Latinos have high hurdles to jump, study shows 2Health News:Esophageal Cancer Risk Less Dire for Certain Patients: Study 2Health News:Esophageal Cancer Risk Less Dire for Certain Patients: Study 3Health News:Blacks Fare Worse Than Whites After Colon Cancer Surgery 2
The SZX9 is one of the top research stereo microscopes in the Olympus line. It has the largest zoom range of any of our stereo microscopes....
... and chromatic correction for the focal plane, ... flat images for observation and photomicrography by ... wavelengths up to the near UV range ... types of low autofluorescence makes these objectives ...
Inquire...
This is the most versatile family of objectives. One and the same set of objectives can be used for all common contrasting methods: Brightfield, darkfield, phase contrast, DIC, epi-fluorescence, and ...
Medicine Products: